SARS-CoV-2 (COVID-19) Envelope Antibody

Infectious Disease, COVID-19

Anti-SARS-CoV-2 (COVID-19) Envelope antibody (9169) was raised against a peptide corresponding to 14 amino acids near the carboxyl terminus of SARS-CoV-2 (COVID-19) Envelope protein.

The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Envelope protein.

SARS-CoV-2 (COVID-19) Envelope Antibody is affinity chromatography purified via peptide column.

IgG

SARS-CoV-2 (COVID-19) Envelope Antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 (COVID-19) Envelope antibody can be stored at 4 ˚ C for three months and -20 ˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

QHD43418

43740570

E

Wuhan seafood market pneumonia virus

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic corona virus E proteins, and also viral replication (3).

Hui et al. Int J Infect Dis. 2020; 91:264-266.

Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Envelope in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (9169, 0.5 μ g/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 envelope protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.

Figure 3 ELISA Validation with SARS-CoV-2 Envelope Recombinant Protein
Antibodies: SARS-CoV-2 (COVID-19) Envelope Antibody, 9169. A direct ELISA was performed using SARS-CoV-2 Envelope recombinant protein (92-730) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 1 ng/mL to 3000 ng/mL.